The researchers showed that, far from affecting the effectiveness of the vaccine, an interval of up to 45 weeks between the two doses improved the immune response to the virus.
This should be reassuring news for countries with less vaccine supplies, who may be concerned about delays in getting second doses to their populations. There is an excellent response to a second dose, even after a delay of 10 months from the firstcommented Professor Andrew Pollard, director of the Oxford Vaccine Group, which developed the vaccine with the Anglo-Swedish pharmaceutical group.
In February, a study from the University of Oxford published in The Lancet had previously indicated that the vaccine was more effective with an interval of three months between doses (81%), than after an interval of six weeks (55%).
A third dose?
In their study published Monday, the researchers also showed that a third dose injected more than six months after the second causes a
significant increase antibodies and causes
sharp rise of the immune response against COVID-19, including against variants.
It is not known whether booster injections will be necessary due to decreased immunity or to increase immunity against the variants of concern., said Teresa Lambe, lead author of these studies.
But the professor notes that research shows that a third dose of the vaccine
is well tolerated and considerably increases the antibody response. This is very encouraging news, if we were to find that a third dose is needed.
The researchers note that the vaccine had
fewer side effects after the second and third doses than after the first.
The AstraZeneca vaccine, which uses the so-called
viral vector (adenovirus), sparked much concern after a link was established between serum and very rare, but often fatal, blood clots.
Many countries have suddenly restricted its use to the elderly and some have stopped using it.
In another study published Monday, the University of Oxford reports that a mixed vaccination schedule combining a dose of AstraZeneca-Oxford vaccine and a dose of Pfizer-BioNTech vaccine injected four weeks apart
generates a strong immune response against COVID-19.
Efficacy varies according to the order of immunization, this study indicates, with one dose of AstraZeneca-Oxford followed by a dose of Pfizer-BioNTech generating a
better immune response than the reverse.
Results for a 12-week interval between the two doses will soon be known and
will have a key role to play in decisions about the future of the UK immunization program, underlined Professor Jonathan Van-Tam, Deputy Chief Medical Officer for England.
Combine two different serums
could offer us even more flexibility, he noted.
In the UK, 84.1% of the adult population received a first dose of COVID-19 vaccine and 61.6% received two doses.